Affiliation:
1. Allentown, PA, USA
2. VA San Diego Healthcare System and University of California, San Diego, USA
3. RDI, London, UK
4. University of Pittsburgh, USA
5. Erasmus Medical Center Rotterdam and University Hospital Utrecht, the Netherlands
Abstract
Understanding resistance to antiretroviral therapy plays an ever more crucial role in managing HIV infection as new agents – including several in new antiretroviral classes – promise better control of multidrug-resistant virus in the developed world. Yet these new drugs have different, and often complex, resistance profiles. At the same time, resistance has assumed a key role in developing countries as access to additional antiretrovirals expands in the face of first-line regimen failures. Every year the International HIV Drug Resistance Workshop gathers leading investigators and resistance-savvy clinicians to share unpublished, peer-reviewed research on the mechanisms, pathogenesis, epidemiology, and clinical implications of resistance to licensed and experimental antivirals. The 2007 workshop, held on 12–16 June, proved particularly notable for its exploration of resistance to two new antiretroviral classes, integrase inhibitors and CCR5 antagonists, as well as to agents that control hepatitis C virus (HCV) infection. This report summarizes most oral presentations from the workshop and many posters.
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference57 articles.
1. Cohen C., Steinhart C.R., Ward D.J. Efficacy and safety at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virological response in study TMC125-C223.16th International AIDS Conference.13–18 August 2006. Toronto, Canada. Abstract TUPE0061.